Fibroblast activation protein: A potential therapeutic target in cancer

Cancer Biology and Therapy

Volumn 13, Issue 3, 2012, Pages 123-129

  Liu, Rui ^a   Li, Hui ^a   Liu, Liang ^a   Yu, Jinpu ^a   Ren, Xiubao ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Fibroblast activation protein; Inhibitor; Seprase; Serine protease; Stroma; Therapy; Tumor

Indexed keywords

DOCETAXEL; DOXORUBICIN; FIBROBLAST ACTIVATION PROTEIN; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY FAP5 DM1; PRODRUG; PROTOXIN; PT 630; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SIBROTUZUMAB; TALABOSTAT; TUMOR VACCINE; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CANCER INVASION; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CANCER; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME STRUCTURE; EPITHELIUM TUMOR; FIBROBLAST; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STROMA; TISSUE DISTRIBUTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; EXTRACELLULAR MATRIX; GELATINASES; HUMANS; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SERINE ENDOPEPTIDASES; TUMOR MICROENVIRONMENT;

EID: 84863116741     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.13.3.18696     Document Type: Review

References (69)

1. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315:1650-9; PMID:3537791
2. Rettig WJ, Chesa PG, Beresford HR, Feickert HJ, Jennings MT, Cohen J, et al. Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets. Cancer Res 1986; 46: 6406-12; PMID:2877731
3. Rettig WJ, Su SL, Fortunato SR, Scanlan MJ, Raj BK, Garin-Chesa P, et al. Fibroblast activation protein: purification, epitope mapping and induction by growth factors. Int J Cancer 1994; 58:385-92; PMID: 7519584; http://dx.doi.org/10.1002/ijc.2910580314
4. Aoyama A, Chen WT. A 170-kDa membrane-bound protease is associated with the expression of invasiveness by human malignant melanoma cells. Proc Natl Acad Sci U S A 1990; 87:8296-300; PMID:2172980; http://dx.doi.org/10.1073/pnas.87. 21.8296
5. Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A 1994; 91:5657-61; PMID:7911242; http://dx. doi.org/10.1073/pnas.91.12.5657
6. Niedermeyer J, Enenkel B, Park JE, Lenter M, Rettig WJ, Damm K, et al. Mouse fibroblast-activation protein-conserved Fap gene organization and biochemical function as a serine protease. Eur J Biochem 1998; 254:650-4; PMID:9688278; http://dx.doi.org/10.1046/j.1432-1327.1998.2540650.x
7. Chen WT, Kelly T. Seprase complexes in cellular invasiveness. Cancer Metastasis Rev 2003; 22: 259-69; PMID:12785000; http://dx.doi.org/10.1023/A: 1023055600919
8. Goldstein LA, Ghersi G, Piñeiro-Sánchez ML, Salamone M, Yeh Y, Flessate D, et al. Molecular cloning of seprase: a serine integral membrane protease from human melanoma. Biochim Biophys Acta 1997; 1361:11-9; PMID:9247085
9. Aertgeerts K, Levin I, Shi L, Snell GP, Jennings A, Prasad GS, et al. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem 2005; 280:19441-4; PMID: 15809306; http://dx.doi.org/10.1074/jbc.C500092200
10. Zhang J, Valianou M, Cheng JD. Identification and characterization of the promoter of fibroblast activation protein. [Elite Ed]. Front Biosci (Elite Ed) 2010; 2: 1154-63; PMID:20515787; http://dx.doi.org/10.2741/E175
11. Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol Cancer Ther 2005; 4:351-60; PMID:15767544
12. Christiansen VJ, Jackson KW, Lee KN, McKee PA. Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch Biochem Biophys 2007; 457:177-86; PMID:17174263; http://dx.doi.org/10.1016/j.abb.2006. 11.006
13. Keane FM, Nadvi NA, Yao TW, Gorrell MD. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-a. FEBS J 2011; 278:1316-32; PMID:21314817; http://dx.doi.org/10.1111/j.1742-4658.2011.08051.x
14. Meadows SA, Edosada CY, Mayeda M, Tran T, Quan C, Raab H, et al. Ala657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization. Biochemistry 2007; 46:4598-605; PMID:17381073; http://dx.doi.org/10.1021/bi062227y
15. Dolznig H, Schweifer N, Puri C, Kraut N, Rettig WJ, Kerjaschki D, et al. Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun 2005; 5:10; PMID:16076089
16. Mathew S, Scanlan MJ, Mohan Raj BK, Murty VV, Garin-Chesa P, Old LJ, et al. The gene for fibroblast activation protein alpha (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23. Genomics 1995; 25:335-7; PMID:7774951; http://dx. doi.org/10.1016/0888-7543(95)80157-H
17. Bauer S, Jendro MC, Wadle A, Kleber S, Stenner F, Dinser R, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther 2006; 8:R171; PMID: 17105646; http://dx.doi.org/10.1186/ar2080
18. Milner JM, Kevorkian L, Young DA, Jones D, Wait R, Donell ST, et al. Fibroblast activation protein alpha is expressed by chondrocytes following a proinflammatory stimulus and is elevated in osteoarthritis. Arthritis Res Ther 2006; 8:R23; PMID:16507127; http://dx.doi.org/10.1186/ar1877
19. Wang XM, Yao TW, Nadvi NA, Osborne B, McCaughan GW, Gorrell MD. Fibroblast activation protein and chronic liver disease. Front Biosci 2008; 13:3168-80; PMID:17981786; http://dx.doi.org/10. 2741/2918
20. Acharya PS, Zukas A, Chandan V, Katzenstein AL, Puré E. Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Hum Pathol 2006; 37: 352-60; PMID:16613331; http://dx.doi.org/10.1016/j.humpath.2005.11.020
21. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A 1990; 87:7235-9; PMID:2402505; http://dx.doi.org/10. 1073/pnas.87.18.7235
22. Dohi O, Ohtani H, Hatori M, Sato E, Hosaka M, Nagura H, et al. Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours. Histopathology 2009; 55:432-40; PMID:19817894; http://dx.doi.org/10.1111/j.1365-2559.2009. 03399.x
23. Abbas O, Richards JE, Mahalingam M. Fibroblast-activation protein: a single marker that confidently differentiates morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma. Mod Pathol 2010; 23:1535-43; PMID:20711172; http://dx.doi. org/10.1038/modpathol.2010.142
24. Bae S, Park CW, Son HK, Ju HK, Paik D, Jeon CJ, et al. Fibroblast activation protein alpha identifies mesenchymal stromal cells from human bone marrow. Br J Haematol 2008; 142:827-30; PMID:18510677; http://dx.doi.org/10. 1111/j.1365-2141.2008.07241.x
25. Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun JG, McKee PA. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 2006; 107:1397-404; PMID:16223769; http://dx.doi. org/10.1182/blood-2005- 08-3452
26. Lee KN, Jackson KW, Christiansen VJ, Chung KH, McKee PA. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood 2004; 103:3783-8; PMID:14751930; http://dx.doi. org/10.1182/blood-2003-12-4240
27. Goodman JD, Rozypal TL, Kelly T. Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells. Clin Exp Metastasis 2003; 20:459-70; PMID:14524536; http://dx.doi.org/10.1023/A: 1025493605850
28. Wen Y, Wang CT, Ma TT, Li ZY, Zhou LN, Mu B, et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci 2010; 101:2325-32; PMID:20804499; http://dx.doi.org/10. 1111/j.1349-7006.2010.01695.x
29. Cheng JD, Dunbrack RL, Jr., Valianou M, Rogatko A, Alpaugh RK, Weiner LM. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 2002; 62:4767-72; PMID:12183436
30. Chen H, Yang WW, Wen QT, Xu L, Chen M. TGF-beta induces fibroblast activation protein expression; fibroblast activation protein expression increases the proliferation, adhesion, and migration of HO-8910PM [corrected]. [corrected]. Exp Mol Pathol 2009; 87: 189-94; PMID:19747910; http://dx.doi.org/10.1016/j.yexmp.2009.09.001
31. Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas 2008; 37:154-8; PMID:18665076; http://dx.doi.org/10.1097/MPA.0b013e31816618ce
32. O'Brien P, O'Connor BF. Seprase: an overview of an important matrix serine protease. Biochim Biophys Acta 2008; 1784:1130-45; PMID:18262497
33. Ramirez-Montagut T, Blachere NE, Sviderskaya EV, Bennett DC, Rettig WJ, Garin-Chesa P, et al. FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene 2004; 23: 5435-46; PMID:15133496; http://dx.doi.org/10.1038/sj.onc.1207730
34. Tsujimoto H, Nishizuka S, Redpath JL, Stanbridge EJ. Differential gene expression in tumorigenic and nontumorigenic HeLa x normal human fibroblast hybrid cells. Mol Carcinog 1999; 26:298-304; PMID: 10569806; http://dx.doi.org/10.1002/(SICI)1098-2744 (199912)26:4〈298::AID-MC8〉3. 0.CO;2-M
35. Ariga N, Sato E, Ohuchi N, Nagura H, Ohtani H. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer 2001; 95:67-72; PMID:11241314; http://dx.doi.org/10.1002/1097- 0215(20010120)95:1〈67::AID-IJC1012〉3. 0.CO;2-U
36. Laconi E. The evolving concept of tumor microenvironments. Bioessays 2007; 29:738-44; PMID:17621638; http://dx.doi.org/10.1002/bies.20606
37. Lee HO, Mullins SR, Franco-Barraza J, Valianou M, Cukierman E, Cheng JD. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 2011; 11:245; PMID:21668992; http://dx.doi.org/10.1186/1471-2407-11-245
38. Wang XM, Yu DM, McCaughan GW, Gorrell MD. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology 2005; 42:935-45; PMID: 16175601; http://dx.doi.org/10. 1002/hep.20853
39. Monsky WL, Lin CY, Aoyama A, Kelly T, Akiyama SK, Mueller SC, et al. A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res 1994; 54:5702-10; PMID:7923219
40. Milner JM, Kevorkian L, Young DA, Jones D, Wait R, Donell ST, et al. Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis. Arthritis Res Ther 2006; 8:R23; PMID:16507127; http://dx.doi.org/10.1186/ar1877
41. Artym VV, Kindzelskii AL, Chen WT, Petty HR. Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta1 integrins and the cytoskeleton. Carcinogenesis 2002; 23:1593-601; PMID:12376466; http://dx.doi.org/10.1093/ carcin/23.10.1593
42. Mueller SC, Ghersi G, Akiyama SK, Sang QX, Howard L, Pineiro-Sanchez M, et al. A novel protease-docking function of integrin at invadopodia. J Biol Chem 1999; 274:24947-52; PMID:10455171; http://dx.doi.org/10. 1074/jbc.274.35.24947
43. Mentlein R, Hattermann K, Hemion C, Jungbluth AA, Held-Feindt J. Expression and role of the cell surface protease seprase/fibroblast activation protein-α (FAP-α) in astroglial tumors. Biol Chem 2011; 392:199-207; PMID:20707604; http://dx.doi.org/10.1515/BC.2010. 119
44. Santos AM, Jung J, Aziz N, Kissil JL, Puré E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest 2009; 119:3613-25; PMID:19920354; http://dx.doi.org/10. 1172/JCI38988
45. Wäster P, Rosdahl I, Gilmore BF, Seifert O. Ultraviolet exposure of melanoma cells induces fibroblast activation protein-α in fibroblasts: Implications for melanoma invasion. Int J Oncol 2011; 39:193-202; PMID: 21491083
46. Koperek O, Scheuba C, Puri C, Birner P, Haslinger C, Rettig W, et al. Molecular characterization of the desmoplastic tumor stroma in medullary thyroid carcinoma. Int J Oncol 2007; 31:59-67; PMID:17549405
47. Huang Y, Simms AE, Mazur A, Wang S, León NR, Jones B, et al. Fibroblast activation protein-α promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis 2011; 28:567-79; PMID:21604185; http://dx.doi.org/10.1007/s10585-011-9392-x
48. Huang Y, Wang S, Kelly T. Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res 2004; 64:2712-6; PMID:15087384; http://dx.doi.org/10.1158/0008-5472.CAN-03- 3184
49. Aimes RT, Zijlstra A, Hooper JD, Ogbourne SM, Sit ML, Fuchs S, et al. Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost 2003; 89:561-72; PMID: 12624642
50. Santos AM, Jung J, Aziz N, Kissil JL, Puré E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest 2009; 119:3613-25; PMID:19920354; http://dx.doi.org/10. 1172/JCI38988
51. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010; 330:827-30; PMID: 21051638; http://dx.doi.org/10.1126/science.1195300
52. Wang T, Shi W. Expression of fibroblast activation proteins in corneal stromal neovascularization. Curr Eye Res 2009; 34:112-7; PMID:19219682; http://dx.doi. org/10.1080/02713680802607732
53. Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007; 13:1736-41; PMID:17363526; http://dx.doi.org/10. 1158/1078-0432.CCR-06-1746
54. Adams S, Miller GT, Jesson MI, Watanabe T, Jones B, Wallner BP. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res 2004; 64:5471-80; PMID:15289357; http://dx.doi.org/10.1158/0008-5472.CAN-04- 0447
55. Jones B, Adams S, Miller GT, Jesson MI, Watanabe T, Wallner BP. Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Blood 2003; 102:1641-8; PMID:12738665; http://dx. doi.org/10.1182/blood-2003-01- 0208
56. Narra K, Mullins SR, Lee HO, Strzemkowski-Brun B, Magalong K, Christiansen VJ, et al. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther 2007; 6:1691-9; PMID: 18032930; http://dx.doi.org/10. 4161/cbt.6.11.4874
57. Eager RM, Cunningham CC, Senzer N, Richards DA, Raju RN, Jones B, et al. Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol) 2009; 21:464-72; PMID: 19501491; http://dx.doi.org/10.1016/j.clon.2009.04.007
58. Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003; 9:1639-47; PMID:12738716
59. Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, Jäger D, Renner C, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 2003; 26:44-8; PMID:12624517; http://dx.doi.org/10.1159/000069863
60. Ostermann E, Garin-Chesa P, Heider KH, Kalat M, Lamche H, Puri C, et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res 2008; 14:4584-92; PMID:18628473; http://dx.doi.org/10.1158/1078-0432.CCR-07-5211
61. LeBeau AM, Brennen WN, Aggarwal S, Denmeade SR. Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol Cancer Ther 2009; 8:1378-86; PMID:19417147; http://dx. doi.org/10.1158/1535- 7163.MCT-08-1170
62. Lo PC, Chen J, Stefflova K, Warren MS, Navab R, Bandarchi B, et al. Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers. J Med Chem 2009; 52:358-68; PMID:19093877; http://dx.doi.org/10.1021/jm801052f
63. Huang S, Fang R, Xu J, Qiu S, Zhang H, Du J, et al. Evaluation of the tumor targeting of a FAPa-based doxorubicin prodrug. J Drug Target 2011; 19:487-96; PMID:21284542; http://dx.doi.org/10.3109/1061186X. 2010.511225
64. Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 2009; 4:e7965; PMID:19956757; http://dx.doi.org/10.1371/journal.pone.0007965
65. Bauer S, Adrian N, Siebenborn U, Fadle N, Plesko M, Fischer E, et al. Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8. Cancer Immun 2009; 9:2; PMID:19267427
66. Yi YM, Zhang G, Zeng J, Huang SC, Li LL, Fang R, et al. A new tumor vaccine: FAPt-MT elicits effective antitumor response by targeting indolamine2,3-dioxygenase in antigen presenting cells. Cancer Biol Ther 2011; 11:866-73; PMID:21372637; http://dx.doi.org/10.4161/cbt.11.10.15179
67. Burckhart T, Thiel M, Nishikawa H, Wüest T, Müller D, Zippelius A, et al. Tumor-specific cross-linking of GITR as costimulation for immunotherapy. J Immunother 2010; 33:925-34; PMID:20948444; http://dx.doi.org/ 10.1097/CJI.0b013e3181f3cc87
68. Loeffler M, Krüger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006; 116:1955-62; PMID:16794736; http://dx.doi.org/10.1172/JCI26532
69. Puré E. The road to integrative cancer therapies: emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer. Expert Opin Ther Targets 2009; 13:967-73; PMID:19606930; http://dx.doi.org/10.1517/14728220903103841